



November 2005

EP07-A2

Interference Testing in Clinical Chemistry; Approved Guideline—Second Edition

This document provides background information, guidance, and experimental procedures for investigating, identifying, and characterizing the effects of interfering substances on clinical chemistry test results.

.....

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

Clinical and Laboratory Standards Institute

Setting the standard for quality in clinical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing clinical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are addressed according to the consensus process by a committee of experts.

Appeals Process

If it is believed that an objection has not been adequately addressed, the process for appeals is documented in the CLSI Administrative Procedures.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For further information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: 610.688.0100
F: 610.688.0700
www.clsi.org
standard@clsi.org

ISBN 1-56238-584-4
ISSN 0273-3099

EP07-A2
Vol. 25 No. 27
Replaces EP7-A
Vol. 22 No. 27

Interference Testing in Clinical Chemistry; Approved Guideline— Second Edition

Volume 25 Number 27

Robert J. McEnroe, PhD
Mary F. Burritt, PhD
Donald M. Powers, PhD
Douglas W. Rheinheimer, MT
Brian H. Wallace, PhD

Abstract

Clinical and Laboratory Standards Institute document EP07-A2—*Interference Testing in Clinical Chemistry; Approved Guideline—Second Edition* is intended to promote uniformity in the evaluation of interference characteristics of clinical laboratory measurement procedures. EP07 describes procedures for manufacturers to screen potentially interfering substances, to quantify interference effects, and to confirm interference in patient samples. This document also describes procedures for clinical laboratories to verify interference claims, and to investigate discrepant results caused by unsuspected interfering substances. Detailed examples are given. EP07 also contains background information on interference testing concepts, tables of recommended test concentrations for analytes and potential interference, and data collection and analysis worksheets.

Clinical and Laboratory Standards Institute (CLSI). *Interference Testing in Clinical Chemistry; Approved Guideline—Second Edition*. CLSI document EP07-A2 (ISBN 1-56238-584-4). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2005.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org.



Copyright ©2005 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation

CLSI. *Interference Testing in Clinical Chemistry; Approved Guideline—Second Edition*. CLSI document EP07-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2005.

Proposed Guideline

August 1986

Approved Guideline

December 2002

Approved Guideline—Second Edition

November 2005

ISBN 1-56238-584-4
ISSN 0273-3099

Committee Membership

Area Committee on Evaluation Protocols

Luann Ochs, MS
Chairholder
Roche Diagnostics Corporation
Indianapolis, Indiana

Jan S. Krouwer, PhD
Vice-Chairholder
Krouwer Consulting
Sherborn, Massachusetts

George S. Cembrowski, MD, PhD
Provincial Laboratory for Public
Health
Edmonton, Alberta, Canada

David L. Duewer, PhD
National Institute of Standards and
Technology
Gaithersburg, Maryland

Anders Kallner, MD, PhD
Karolinska Hospital
Stockholm, Sweden

Jacob (Jack) B. Levine, MBA
Bayer Corporation
Tarrytown, New York

Kristian Linnet, MD, PhD
Psychiatric University Hospital
Risskov, Denmark

Kristen L. Meier, PhD
FDA Center for Devices and
Radiological Health
Rockville, Maryland

Daniel W. Tholen, MS
Dan Tholen Statistical Consulting
Traverse City, Michigan

Advisors

David A. Armbruster, PhD,
DABCC, FACB
Abbott Laboratories
Abbott Park, Illinois

R. Neill Carey, PhD, FACB
Peninsula Regional Medical Center
Salisbury, Maryland

Carl C. Garber, PhD, FACB
Quest Diagnostics, Incorporated
Lyndhurst, New Jersey

Patricia E. Garrett, PhD
Boston Biomedica, Inc.
Portland, Maine

Martin H. Kroll, MD
Dallas VA Medical Center
Dallas, Texas

Donald M. Powers, PhD
Powers Consulting Services
Pittsford, New York

Max Robinowitz, MD
FDA Center for Devices and
Radiological Health
Rockville, Maryland

Gian Alfredo Scassellati, PhD
Ente Nazionale Italiano Di
Unificazione
Turin, Italy

Jack Zakowski, PhD
Beckman Coulter, Inc.
Brea, California

Working Group on Interference Testing

Robert J. McEnroe, PhD
Chairholder
Roche Diagnostics Operations,
Inc.
Indianapolis, Indiana

Mary E. Burritt, PhD
Mayo Clinic
Rochester, Minnesota

Donald M. Powers, PhD
Powers Consulting Services
Pittsford, New York

Douglas W. Rheinheimer, MT
FDA Center for Devices and
Radiological Health
Rockville, Maryland

Brian H. Wallace, PhD
LifeScan, Inc.
Milpitas, California

Staff

Clinical and Laboratory Standards
Institute
Wayne, Pennsylvania

John J. Zlockie, MBA
Vice President, Standards

Lois M. Schmidt, DA
Staff Liaison

Donna M. Wilhelm
Editor

Melissa A. Lewis
Assistant Editor

Contents

Abstract..... i

Committee Membership..... iii

Foreword..... vii

1 Scope..... 1

2 Introduction..... 1

 2.1 Measurement Procedures..... 1

 2.2 Concepts and Scientific Principles..... 2

3 Standard Precautions..... 4

4 Definitions 5

5 Decision Criteria for Interference Testing 8

 5.1 Clinical Acceptability Criteria 9

 5.2 Statistical Significance and Power..... 9

 5.3 Analyte Test Concentrations..... 10

 5.4 Potential Interfering Substances 10

 5.5 Interferent Test Concentrations..... 11

6 Quality Assurance and Safety 12

 6.1 Training and Familiarization..... 12

 6.2 Precision Verification 12

 6.3 Trueness Verification..... 12

 6.4 Carryover Assessment 12

 6.5 Quality Control 12

 6.6 Safety and Waste Disposal..... 13

7 Estimation of Interference Characteristics 13

 7.1 Interference Screen 13

 7.2 Characterization of Interference Effects 20

 7.3 Evaluating Combinations of Analyte and Interferent(s) 26

8 Evaluating Interference Using Patient Specimens 26

 8.1 Experimental Design..... 26

 8.2 Comparative Measurement Procedure..... 27

 8.3 Patient Populations 27

 8.4 Experimental Procedure..... 28

 8.5 Data Analysis..... 28

 8.6 Interpretation of Results..... 31

9 Establishing, Validating, and Verifying Interference Claims 31

 9.1 Establishing Interference Claims 32

 9.2 Verifying Analytical Specificity 34

 9.3 Validating Analytical Specificity..... 35

 9.4 Verifying Interference and Specificity Claims 36

Contents (Continued)

10 Investigating Discrepant Patient Results.....36

 10.1 Verify System Performance.....37

 10.2 Evaluate Sample Quality37

 10.3 Confirm the Original Result.....37

 10.4 Identify Potentially Interfering Substances.....38

 10.5 Determine the Probable Interferent.....38

 10.6 Characterize the Interference39

References.....40

Appendix A. Guidelines for Specific Measurement Procedures43

Appendix B. Analyte Test Concentrations46

Appendix C. Interferent Test Concentrations49

Appendix D. Interference Test Concentrations for Endogenous Analytes75

Appendix E. Worksheets79

Appendix F. Calculation of Replicates for Dose-Response Tests87

Appendix G. Preparation of Test Solutions for Interference Testing90

Summary of Consensus Comments and Committee Responses96

Summary of Consensus/Delegate Comments and Committee Responses.....101

The Quality System Approach.....104

Related CLSI/NCCLS Publications.....105

Foreword

Interfering substances can be a significant source of error in clinical laboratory measurements.¹⁻³ Such errors may, in some cases, represent a hazard to the patient. While precision is routinely monitored by internal quality control, and accuracy can be verified by comparison to reference materials or procedures, laboratories cannot easily detect error caused by interfering substances. Therefore, manufacturers of *in vitro* diagnostic (IVD) analytical systems must include evaluation of the effects of the potentially interfering substances in their risk analyses at the design stage.

Although continuously improving the specificity of measurement procedures is a desirable goal, compromise is sometimes necessary to meet the needs of clinical laboratories. The purpose of this document is to enable manufacturers and laboratories to evaluate interfering substances in the context of medical needs and to inform their customers of known sources of medically significant error. This guideline identifies potential hazards to be evaluated in the risk management process described in ISO 14971.⁴

To accommodate the variety of existing and future measurement procedures, we provided guidance instead of rigid protocols. The subcommittee struck a balance between consistency of structured protocols and flexibility to accommodate the technology being evaluated. Laboratorians and manufacturers need to understand the scientific concepts, make informed choices, and work together toward the common goal of improving patient care. Clearly, identifying an interference effect, evaluating its medical significance, determining its underlying cause, and ultimately improving the measurement procedure requires close cooperation between laboratory and manufacturer.

Background information is included to explain key chemical and statistical concepts. Please note that this document focuses on interference with analytical processes. It does not address physiological effects caused by drugs and their metabolites. The IFCC has issued a series of recommendations on drug effects⁵⁻⁷ that have been published as a compendium.⁸ Comprehensive literature surveys of the analytical and physiological effects of drugs and other substances have been published.⁹⁻¹¹

The basic substance of EP07-A2 remains unchanged. A thorough review of the exogenous and endogenous compounds recommended for testing was performed. Each drug or drug metabolite was systematically categorized into specific drug classes. This guideline was developed to inform the reader and provide a logical approach to complete the evaluation of the effects of potentially interfering compounds on the measurement procedure test results. The guideline is intended to make the decision easier by basing it on reasonable, objective criteria. We now ask the reader to give us comments and suggestions. Each comment and suggestion will be considered carefully at the next revision.

A Note on Terminology

CLSI, as a global leader in standardization, is firmly committed to achieving global harmonization wherever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. CLSI recognizes that medical conventions in the global metrological community have evolved differently in the United States, Europe, and elsewhere; that these differences are reflected in CLSI, ISO, and CEN documents; and that legally required use of terms, regional usage, and different consensus timelines are all obstacles to harmonization. Despite these obstacles, CLSI recognizes that harmonization of terms facilitates the global application of standards and is an area that needs immediate attention. Implementation of this policy must be an evolutionary and educational process that begins with new projects and revisions of existing documents.

In order to align the usage of terminology in this document with that of ISO, the following terms are used in EP07-A2:

The term *trueness* has replaced the term *accuracy* when referring to the closeness of agreement between the *average value* obtained from a large series of test results and an accepted reference value. *Accuracy*, in its metrological sense, refers to the closeness of the agreement between the result of a *single measurement* and a true value of a measurand, thus comprising both random and systematic effects.

The term *measurement procedure* has replaced the terms *method*, *analytical method*, and *analytical system* for a set of operations used in the performance of particular measurements according to a given method. The term *assay* has been replaced by *method*, *measurement procedure*, *measurement*, *analyze*, and *analysis* as appropriate. At this time, due to user unfamiliarity, the term *examination* is not used in this edition of EP07.

The terms *specimen* and *sample* are both used in this document, with *specimen* reserved for material collected directly from the patient, and *sample* reserved for aliquots of the patient specimen and for processed materials (e.g., PT samples, reference materials).

The term *analyte* is used appropriately in this document. The term *analyte* is used to represent the particular component of interest to the patient diagnosis, while the term *measurand* is used to describe the specific quantity that is measured by a particular measurement procedure (i.e., the measurand describes what is actually causing the result of the measurement). This important difference can be subtle, since it can be due to the detection of different measurands in the procedures being compared. The term *precision* is a measure of “closeness of agreement between independent test/measurement results obtained under stipulated conditions.”¹² The terms in this document are consistent with uses defined in the ISO 3534 and ISO 5725 series of standards.

At this time, due to user unfamiliarity and for the sake of the practicability of the guideline, it is important to point out that the working group has chosen not to replace the term *interfering substance* or *interferent* with the VIM (*International Vocabulary of Basic and General Terms in Metrology*) term *influence quantity* (i.e., quantity that is not the measurand but that affects the result of the measurement). The users of EP07 should understand that the fundamental meanings of the terms are identical, and to facilitate understanding, the terms are defined along with their ISO counterparts in the guideline’s Definitions section.

All terms and definitions will be reviewed again for consistency with international use, and revised appropriately during the next scheduled revision of this document.

Key Words

Evaluation, hazard analysis, interference, interferent, matrix effects, performance claims, risk management, specificity, validation, verification

Interference Testing in Clinical Chemistry; Approved Guideline—Second Edition

1 Scope

This document is intended to serve two purposes:

- 1) to assist manufacturers and other developers of laboratory measurement procedures in characterizing the susceptibility of measurement procedures to interfering substances, by offering scientifically valid experimental designs, by specifying the relevant substances and concentrations to be tested, and by clarifying appropriate data analysis and interpretation, so that potential hazards can be evaluated and meaningful interference claims may be provided to users; and
- 2) to assist clinical laboratories in investigating discrepant results due to interfering substances, by defining a systematic investigation strategy, by specifying data collection and analysis requirements, and by promoting greater cooperation between laboratory users and manufacturers, so that new interferences can be identified, disclosed, and ultimately eliminated.

This guideline is intended for manufacturers of *in vitro* diagnostic medical devices and clinical laboratories.

Manufacturers and other developers of laboratory measurement procedures are responsible for characterizing the analytical performance of their procedures and analyzing hazards to patients caused by errors due to interfering substances. Manufacturers are required to provide information about interference susceptibility to those who use their systems. **NOTE:** The term “manufacturer,” for the purpose of this document, is used to mean anyone that develops a measurement procedure for use in a clinical laboratory.

Clinical laboratories are responsible for ensuring that measurement procedures are specific enough to meet the needs of their physician clients. Laboratories should also investigate discrepant results, identify interfering substances, and provide objective feedback to the manufacturers who supply their analysis systems.

2 Introduction

2.1 Measurement Procedures

Any measurement procedure, quantitative or qualitative, may be subject to interference. This document is written for a broad spectrum of measurement procedures and analyzers. Modification may be necessary to accommodate the particular characteristics of the procedure being evaluated. Two specific method principles (i.e., separation techniques and immunochemical measurement procedures) are discussed in Appendix A.

2.1.1 Specimen Type

Interferences with measurement procedures that use serum, plasma, whole blood, cerebrospinal fluid, urine, and most other body fluids may be evaluated using this guideline.

2.1.2 Interfering Substances

Potentially interfering substances may originate from the following endogenous and exogenous sources: